Doctors target Catalyst Pharma’s forthcoming pricing on old-turned-new med Firdapse

Tracy Staton

A new group of activist doctors has joined the drug protests. This time, it's neuromuscular specialists, and they're targeting a drug, , that's likely to turn treatment of a rare disease from a no-cost endeavor to an expensive affair.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS